Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.
Jia LiuYanjin HuYuan XuYumei JiaLi MiaoGuang WangPublished in: International journal of endocrinology (2017)
For an initial therapy in overweight/obese patients with newly diagnosed T2D, exenatide causes a better glycemic control than metformin. This trial is registered with NCT03297879.
Keyphrases
- glycemic control
- newly diagnosed
- weight loss
- type diabetes
- bariatric surgery
- blood glucose
- weight gain
- study protocol
- clinical trial
- obese patients
- open label
- phase ii
- adipose tissue
- physical activity
- insulin resistance
- stem cells
- cardiovascular disease
- metabolic syndrome
- body mass index
- cell therapy
- skeletal muscle
- smoking cessation